3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lung Neoplasms
8
Colorectal Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Neoplasms
3
Smoking Cessation
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Colonic Neoplasms
2
Wilms Tumor
1
Venous Thromboembolism
1
Uveal Melanoma
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Recurrence
1
Pulmonary Disease, Chronic Obstructive
1
Opioid-Related Disorders
1
Neuroblastoma
1
Neoplastic Cells, Circulating
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Inflammation
1
Hodgkin Disease
1
Hepatic Veno-Occlusive Disease
1
HPV Positive Oropharyngeal Squamous Cell Carcinoma
1
Fibrosis
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
16
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Taxes
8
Folfox protocol
8
Drug Therapy
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
tremelimumab
6
Endoscopy, Digestive System
6
Endoscopy
6
Biopsy
6
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma Of Esophagus
×
Hematologic Tests
×
Clear all
NCT02610764
2017-04-13
ESO-CTC
University Hospital Freiburg
Phase NA
Completed
19 enrolled